


1 / 7

F i g . 1




MODIFIED THIOREDOXIN

Ishii et al.

Appl. No.: 10/551,488 Atty Docket: SAEG129.015APC
REPLACEMENT SHEET

2 / 7

F i g . 2



NOT AVAILABLE COPY


MODIFIED THIOREDOXIN

Ishii et al.

Appl. No.: 10/551,488 Atty Docket: SAEG129.015APC
REPLACEMENT SHEET

3 / 7


Fig. 3



REST AVAILABLE COPY


4 / 7

Fig. 4



5 / 7

F i g . 5



BEST AVAILABLE COPY

MODIFIED THIOREDOXIN


Ishii et al.

Appl. No.: 10/551,488 Atty Docket: SAEG129.015APC
REPLACEMENT SHEET

6 / 7


Fig. 6

WT-TRX




0.5%	5.3%
84.0%	10.2%

CS-TRX



0.8%	5.9%
74.5%	18.7%

C35S-TRX




1.2%	19.0%
54%	25.8%

MODIFIED THIOREDOXIN

Ishii et al.

Appl. No.: 10/551,488 Atty Docket: SAEG129.015APC
REPLACEMENT SHEET

7 / 7
Fig. 7



EST AVAILABLE COPY